News
Expansion of the peptide hormone antibody portfolio
August 23 2010
Product launch: Pig NGAL ELISA Kit (KIT 044)
August 12 2010
AACC/Clinical Lab Expo 2010, July 27-29, Anaheim, CA
July 06 2010
IUTOX 2010, July 19-23, Barcelona, Spain
June 30 2010
BioPorto Diagnostics at the ERA-EDTA Congress, Munich, June 25-28
June 14 2010
BioPorto Diagnostics at APCN 2010, June 5-8, Seoul, Korea
May 21 2010
Presentation of The NGAL Test data at the BRS/RA Conference, May 17-20, Manchester, UK
May 14 2010
Product launch: new monoclonal antibodies available
May 07 2010
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
BioPorto Diagnostics obtains Quality Management Certification
February 18 2010
AACC/Clinical Lab Expo 2010, July 27-29, Anaheim, CA
July 06 2010 by BioPorto Diagnostics
The AACC/Clinical Laboratory Expo is the leading event for clinical chemistry, clinical laboratory science and laboratory medicine products and services.
More than 20.000 participants are expected to attend the 2010 AACC/Clinical Lab Expo, making it a unique event for showcasing the company’s forthcoming NGAL clinical chemistry test.
Booth
BioPorto Diagnostics will be at booth 6301 on all congress days. Members of the sales and marketing team and management will be available for discussions concerning licensing opportunities, partnering and distribution rights. Please refer to the contact details below to make an appointment.
Poster presentations
BioPorto Diagnostics is presenting three scientific posters on NGAL at the meeting:
Poster No. A-18 - Evaluation of newly developed ELISAs for rat, mouse, dog and pig NGAL
Tuesday, July 27, 10:00 am – 12:30 pm / Animal Clinical Chemistry
Poster No. B-167 - Evaluation of a fully automated NGAL particle-enhanced turbidimetric test
Tuesday, July 27, 2:00 pm – 4:30 pm / Proteins/Enzymes
Poster No. C-33 - Urinary and plasma NGAL levels reflect the severity of acute kidney injury
Wednesday, July 28, 10:00 am – 12:30 pm / Clinical Studies/Outcomes
NGAL and The NGAL Test
NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal status markers and has a proportionate response to injury.
The NGAL Test will be available for a wide range of clinical chemistry analyzers and will be launched in the beginning of 2011. The NGAL Test will be able to determine NGAL levels in both urine and plasma within a standard routine timeframe.
For more information or to set up an appointment, please contact:
Klaus Boberg Pedersen, Human Diagnostics Product Manager, kbp@bioporto.com
Trine Overgaard Østerbye, Sales and Marketing Manager, toe@bioporto.com
Ishan Gupta, Business Development Manager, Sales, ig@bioporto.com
For further information on the event: http://www.aacc.org/events/2010am/pages/default.aspx
